Carmell Corp. Files 8-K with Financials

Ticker: XAGEW · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1842939

Carmell Corp 8-K Filing Summary
FieldDetail
CompanyCarmell Corp (XAGEW)
Form Type8-K
Filed DateNov 20, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001, $11.50
Sentimentneutral

Sentiment: neutral

Topics: disclosure, financials, corporate-actions

TL;DR

Carmell Corp. dropped an 8-K with financials on Nov 20. Check it out.

AI Summary

Carmell Corp. announced on November 20, 2024, a Regulation FD Disclosure and the filing of Financial Statements and Exhibits. The company, formerly known as Carmell Therapeutics Corp. and ALPHA HEALTHCARE ACQUISITION CORP III, is incorporated in Delaware and operates in the Surgical & Medical Instruments & Apparatus industry.

Why It Matters

This filing provides updated financial information and disclosures for Carmell Corp., which is crucial for investors to assess the company's current financial health and strategic direction.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, not indicating any immediate operational or financial distress.

Key Numbers

  • 001-40228 — Commission File Number (Identifies the company's SEC filing history)
  • 86-1645738 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • Carmell Corp. (company) — Registrant
  • November 20, 2024 (date) — Date of earliest event reported
  • Carmell Therapeutics Corp (company) — Former company name
  • ALPHA HEALTHCARE ACQUISITION CORP III (company) — Former company name
  • 2403 Sidney Street, Suite 300 (address) — Business and mailing address
  • Pittsburgh, Pennsylvania (location) — City and State of business address
  • 15203 (zip_code) — Zip code of business address

FAQ

What specific financial statements or exhibits are being filed with this 8-K?

The filing explicitly states 'Financial Statements and Exhibits' are included, but the specific details of these documents are not provided in the excerpt.

What is the primary reason for this 8-K filing?

The filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', indicating it's for public disclosure of material information and financial updates.

When did Carmell Corp. change its name from Carmell Therapeutics Corp?

The filing indicates the date of the name change from Carmell Therapeutics Corp. to Carmell Corp. was July 27, 2023.

What industry does Carmell Corp. operate in?

Carmell Corp. is classified under the 'Surgical & Medical Instruments & Apparatus' industry, with SIC code 3841.

What is the company's fiscal year end?

The company's fiscal year ends on December 31st.

Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-11-20 16:30:18

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share CTCX The Nasdaq Stock Mar
  • $11.50 — of Common Stock at an exercise price of $11.50 CTCXW The Nasdaq Stock Market LLC

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 20, 2024, Carmell Corporation (the "Company") is furnishing with this Current Report on Form 8-K an investor presentation (the "Corporate Presentation") for meetings with certain investors on or after November 20, 2024. The Corporate Presentation, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, discusses recent corporate developments, the Company's products, and related marketing efforts. The information contained in this Item 7.01, including Exhibit 99.1 furnished herewith, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Corporate Presentation (November 20, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 20, 2024 By: /s/ Bryan J. Cassaday Bryan J. Cassaday Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.